-
7 drugs were approved for clinical use in one day, and 5 were oncology drugs
Time of Update: 2022-04-15
According to CDE, the recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection HLX301 independently developed by Henlius has been approved by the State Food and Drug Administration to conduct Phase 1 clinical research in China, and is intended to be used for the treatment of advanced tumors .
-
Investment and Financing Weekly Report｜Anti-tumor drugs, orthopedic robots and other financing exceeded 100 million yuan
Time of Update: 2022-04-15
This round of funds will be used for the company's first phase of two products: the innovative application of the mobile fatty liver disease quantitative detector and the mid-field high-performance magnetic resonance imaging, clinical trials, NMPA/FDA registration and the development of the hospital market and brand building .
-
Cancer: Short-term (2-3 years) adjuvant endocrine therapy is an optional treatment option for breast cancer patients with ER-positive low expression (IHC 1%-10%)
Time of Update: 2022-04-15
Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital , mainly evaluating the use of short-course (2-3 years) adjuvant in patients with ER-positive low-expression (IHC 1%-10%) breast cancer.
-
Front Oncol: Efficacy of TKI combined with anti-PD-1 therapy for early postoperative recurrence of hepatocellular carcinoma
Time of Update: 2022-04-15
Recently, Frontiers in Oncology published a research result from a team from Jinling Hospital of Nanjing University, mainly to evaluate the efficacy of TKI combined with anti-PD-1 therapy for early postoperative recurrence of hepatocellular carcinoma (HCC) and related influencing factors .
-
"Science" Sub-Journal: The mechanism of aspirin's regulation of immune and anti-cancer has been clarified!
Time of Update: 2022-03-07
uk/whri/news-and-events/2022/items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
[8] https:// items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
[8] https:// items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
[8] https:// -events/2022/items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
[8] https:// -events/2022/items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
htmlThe author of this articleYing Yuyanuk/whri/news-and-events/2022/items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
htmlBy Ying Yuyanuk/whri/news-and-events/2022/items/researchers-investigate-previously-unappreciated-mechanisms-in-the-cancer-protective-actions-of-aspirin.
-
【Nature Sub-issue】Breakthrough!
Time of Update: 2022-03-07
Nearly 150 years later, using advanced cell sequencing and state-of-the-art imaging, researchers at Roswell Park Comprehensive Cancer Center have provided a molecular and biological explanation for the discovery, finding that different myeloma may be present in a single patient Cloning and linking distinct genetic changes in myeloma cells to the development of myeloma bone disease .
-
Overview of the latest ESMO guideline recommendations: diagnosis, staging and treatment of germ cell tumors
Time of Update: 2022-03-07
Serum tumor markers (AFP, β-hCG, and LDH) should be monitored before and after orchiectomy and throughout follow-up for accurate staging and risk stratification to guide treatment and monitor recurrence [II, A] .
-
Olaparib maintenance therapy may become a new treatment option for Asian patients with platinum-sensitive recurrent ovarian cancer
Time of Update: 2022-03-07
The study evaluated the efficacy of olaparib maintenance therapy in Asia Efficacy and safety in patients with platinum-sensitive recurrent ovarian cancer, study details are presented below .
Background In patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC), olaparib monotherapy maintenance therapy significantly improved progression-free survival (PFS) compared with placebo .
-
PD-1 monotherapy has progressed, and combination drugs should be carefully selected
Time of Update: 2022-03-07
The synergistic effect of immunotherapy and chemotherapy In the second-line treatment of advanced lung cancer, the general patient's disease progresses after platinum-containing chemotherapy, and the detection of EGFR and ALK driver gene mutations is negative, and immune monotherapy can be used, such as nivolio Monoclonal antibody, pembrolizumab, etc.
-
New Cellular Immunotherapy Failed to Attack mCRPC; This CAR-T Therapy Obtained FDA Orphan Drug Designation Tumor Intelligence
Time of Update: 2022-03-07
02JAMA Oncology: Novel cellular immunotherapy does not improve survival in mCRPC patients, but may be safer than placebo Autologous dendritic cell immunotherapy DCVAC/PCa is a novel immunotherapy designed to activate the immune response against prostate cancer cells, thereby for the treatment of prostate cancer .
-
Eating this way can help treat cancer, and when combined with chemotherapy can significantly increase survival
Time of Update: 2022-03-07
The biggest benefit of the ketogenic diet is that it reduces blood glucose and insulin levels, both of which have been shown to be promoters of pancreatic cancer growth, and glucose is a key energy source for cancer cell proliferation .
-
The "Tumor Immunity Xinhuo China" training program to improve the ability of standardized diagnosis and treatment of tumor immunity was officially launched
Time of Update: 2022-03-07
Unique - Immunotherapy reshapes the new pattern of first-line treatment of advanced liver cancer Moderator: Professor Zhou Jian, Zhongshan Hospital Affiliated to Fudan University Speaker: Professor Sun Huichuan, Zhongshan Hospital Affiliated to Fudan University Although TKIs are effective, the survival benefit is limited and a breakthrough is urgently needed .
-
J Hepatol (IF=25) Ye Qinghai/Ren Ning/Guo Lei/Li Hui/Hong Mingqi discovered a new strategy to enhance immune checkpoint therapy in hepatocellular carcinoma
Time of Update: 2022-03-07
In conclusion, this study finds that PARG acts as an oncogene in HCC by regulating PARG/DDB1/c-Myc signaling and can be used as a biomarker to identify HCC patients who may benefit from anti-PD-1 therapy .
-
A selection of the latest clinical oncology literature (2.6-2.12)
Time of Update: 2022-03-07
The event-free survival results of KEYNOTE-522 with a median follow-up of 39 months suggest that regardless of PD-L1 expression status, pembrolizumab combined with neoadjuvant chemotherapy and continued use in the adjuvant phase can improve survival compared with placebo , which has opened up a new situation for the immunotherapy of high-risk early triple-negative breast cancer .
-
The team of Ji Qinghai/Wang Yulong of Fudan University released a new "Chinese operation" in the world, which cleverly solved the problem of postoperative repair of thyroid cancer
Time of Update: 2022-03-07
Recently, a team led by Professor Ji Qinghai and Professor Wang Yulong from Head and Neck Surgery of Fudan University Affiliated Cancer Hospital launched a new "Chinese procedure" for recurrent laryngeal nerve repair surgery independently designed in the world.
-
Express Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy, Plans to Launch Pivotal Clinical Trial
Time of Update: 2022-03-07
▎WuXi AppTec Content Team Editor Arvinas announced today that new data have been published showing that bavdegalutamide (also known as ARV-110), a novel PROTAC protein degrader targeting the androgen receptor (AR), targets metastatic castration resistance prostate cancer (mCRPC), continues to provide evidence of antitumor activity and patient benefit .
-
The first in the country!
Time of Update: 2022-03-07
In a phase I clinical trial in Australia, Sterling will further explore the safety and efficacy of mRNA-encoded neoantigen-encoding mRNA personalized tumor vaccine therapy in patients with advanced malignant solid tumors .
-
Determining factors of relapse after CAR-T therapy in patients with relapsed and refractory acute B lymphocytic leukemia
Time of Update: 2022-03-07
Table 1: Patient disease characteristics 2 The results of the CRS and neurological events study showed that a total of 30 (59%) patients developed CRS following Tisagenlecleucel infusion, with a median time of 4 days (range: 1-12 days) .
-
Practical analysis of mitochondrial energy metabolism pathway in lung cancer
Time of Update: 2022-03-07
The author's series of methods mined genes and clinical biomarkers that affect lung cancer survival, proving that abnormal genes in mitochondrial energy metabolism pathways may be new targets and biomarkers for diagnosis and treatment of lung cancer, abnormal expression and mutation of some genes affect the prognosis of lung cancer .
-
Early-onset colorectal cancer is increasing, what are the characteristics?
Time of Update: 2022-03-07
2. Strengthen precise screening of high-risk groups and general population screening About 16% of patients with early-onset colorectal cancer have an associated genetic syndrome, and another 25% have a family history of CRC, according to current screening guidelines in the United States and the United Kingdom , they can be screened early .
